Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Nanostructured Lipid Carrier-Mediated Transdermal Delivery System of Glibenclamide for Gestational Diabetes: Pharmacokinetic and Pharmacodynamic Evaluation

Author(s): Ashwini M.*, Preethi Sudheer and Bharani S. Sogali

Volume 21, Issue 10, 2024

Published on: 10 January, 2024

Page: [1386 - 1407] Pages: 22

DOI: 10.2174/0115672018274038231212105440

Price: $65

Abstract

Background: Gestational diabetes mellitus (GDM) poses significant risks during pregnancy for both mother and fetus. Adherence to oral antidiabetic medications, like glibenclamide (GB), can be challenging, necessitating novel drug delivery methods. Nanostructured lipid carriers (NLC) offer a promising approach by efficiently permeating the skin due to their small size and lipid-based composition.

Objective: This study aimed to develop and evaluate transdermal patches loaded with glibenclamide NLCs to treat GDM.

Methods: Glibenclamide NLCs were prepared using hot homogenization with ultrasonication and melt dispersion method. A central composite design was utilized to optimize the formulations. Transdermal patches containing optimized NLCs were developed using HPMC K 100 and Eudragit L polymers. The patches were evaluated for various parameters, and their pharmacokinetic and pharmacodynamic studies were carried out to assess their safety and efficacy.

Results: Optimized NLCs efficiently permeated rat skin. Cell viability studies indicated the nontoxicity of the formulations. NLC-loaded transdermal patches (F2 and F7) showed drug release of 1098 μg/cm2 and 1001.83 μg/cm2 in 24 h, with a 2.5-fold higher flux and permeation coefficient than the GB patch. Pharmacokinetic analysis revealed Tmax of 8 and 10 h and Cmax of 7127 ng/ml and 7960 ng/ml for F2 and F7, respectively, ensuring sustained drug action. AUC0-α was 625681 ng/ml·h and 363625 ng/ml·h for F2 and F7, respectively, indicating improved bioavailability.

Conclusion: Transdermal patches incorporating NLCs hold promise for enhancing glibenclamide's therapeutic efficacy in GDM treatment. Improved skin permeation, sustained drug release, and enhanced bioavailability make NLC-based transdermal patches a potential alternative with better patient compliance.

« Previous Next »
Graphical Abstract

[1]
Hollander, M.H; Paarlberg, K.M; Huisjes, A.J.M Gestational diabetes: A review of the current literature and guidelines. Obstet. Gynecol. Surv., 2007, 62(2), 125-136.
[http://dx.doi.org/10.1097/01.ogx.0000253303.92229.59] [PMID: 17229329]
[2]
Serlin, D.C; Lash, R.W Diagnosis and management of gestational diabetes mellitus. Am. Fam. Physician, 2009, 80(1), 57-62.
[PMID: 19621846]
[3]
Crowther, C.A; Hiller, J.E; Moss, J.R; McPhee, A.J; Jeffries, W.S; Robinson, J.S Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N. Engl. J. Med., 2005, 352(24), 2477-2486.
[http://dx.doi.org/10.1056/NEJMoa042973] [PMID: 15951574]
[4]
Behzadifar, S; Barras, A; Plaisance, V; Pawlowski, V; Szunerits, S; Abderrahmani, A; Boukherroub, R Polymer-based nanostructures for pancreatic beta-cell imaging and non-invasive treatment of diabetes. Pharmaceutics, 2023, 15(4), 1215.
[http://dx.doi.org/10.3390/pharmaceutics15041215] [PMID: 37111699]
[5]
Kalra, S; Gupta, Y; Kalra, B; Singla, R Use of oral anti-diabetic agents in pregnancy: A pragmatic approach. N. Am. J. Med. Sci., 2015, 7(1), 6-12.
[http://dx.doi.org/10.4103/1947-2714.150081] [PMID: 25709972]
[6]
Ali, H.S.M; Hanafy, A.F Glibenclamide nanocrystals in a biodegradable chitosan patch for transdermal delivery: Engineering, formulation, and evaluation. J. Pharm. Sci., 2017, 106(1), 402-410.
[http://dx.doi.org/10.1016/j.xphs.2016.10.010] [PMID: 27866687]
[7]
Ramadon, D; McCrudden, M.T.C; Courtenay, A.J Enhancement strategies for transdermal drug delivery systems: Current trends and applications. Drug Deliv. Transl. Res., 2021, 1-34.
[PMID: 33474709]
[8]
Sezer, A.D Ed,; Application of Nanotechnology in Drug Delivery; InTech, 2014.
[http://dx.doi.org/10.5772/57028]
[9]
Ghate, V.M; Lewis, S.A; Prabhu, P; Dubey, A; Patel, N Nanostructured lipid carriers for the topical delivery of tretinoin. Eur. J. Pharm. Biopharm., 2016, 108, 253-261.
[http://dx.doi.org/10.1016/j.ejpb.2016.07.026] [PMID: 27519827]
[10]
Iqbal, B; Ali, J; Baboota, S Silymarin loaded nanostructured lipid carrier: From design and dermatokinetic study to mechanistic analysis of epidermal drug deposition enhancement. J. Mol. Liq., 2018, 255, 513-529.
[http://dx.doi.org/10.1016/j.molliq.2018.01.141]
[11]
Maroju, R.K; Barash, S; Brisbane, C.E Evaluation of a biologic formulation using customized design of experiment and novel multidimensional robustness diagrams. J. Pharm. Sci., 2018, 107(3), 797-806.
[12]
Gupta, S; Kesarla, R; Chotai, N; Misra, A; Omri, A Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. BioMed Res. Int., 2017, 2017, 1-18.
[http://dx.doi.org/10.1155/2017/5984014] [PMID: 28243600]
[13]
Uprit, S; Kumar Sahu, R; Roy, A; Pare, A Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm. J., 2013, 21(4), 379-385.
[http://dx.doi.org/10.1016/j.jsps.2012.11.005] [PMID: 24227958]
[14]
Poonia, N; Kaur Narang, J; Lather, V; Beg, S; Sharma, T; Singh, B; Pandita, D Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. Colloids Surf. B Biointerfaces, 2019, 181, 756-766.
[http://dx.doi.org/10.1016/j.colsurfb.2019.06.004] [PMID: 31234063]
[15]
Pastor, M; Basas, J; Vairo, C; Gainza, G; Moreno-Sastre, M; Gomis, X; Fleischer, A; Palomino, E; Bachiller, D; Gutiérrez, F.B; Aguirre, J.J; Esquisabel, A; Igartua, M; Gainza, E; Hernandez, R.M; Gavaldà, J; Pedraz, J.L Safety and effectiveness of sodium colistimethate-loaded nanostructured lipid carriers (SCM-NLC) against P. aeruginosa: In vitro and in vivo studies following pulmonary and intramuscular administration. Nanomedicine, 2019, 18, 101-111.
[http://dx.doi.org/10.1016/j.nano.2019.02.014] [PMID: 30849549]
[16]
Aliasgharlou, L; Ghanbarzadeh, S; Azimi, H; Zarrintan, M.H; Hamishehkar, H Nanostructured lipid carrier for topical application of N-acetyl glucosamine. Adv. Pharm. Bull., 2016, 6(4), 581-587.
[http://dx.doi.org/10.15171/apb.2016.072] [PMID: 28101465]
[17]
Marrese, M; Guarino, V; Ambrosio, L Atomic force microscopy: A powerful tool to address scaffold design in tissue engineering. J. Funct. Biomater., 2017, 8(1), 7.
[http://dx.doi.org/10.3390/jfb8010007] [PMID: 28208801]
[18]
Kang, Q; Liu, J; Liu, X.Y; Mo, N.L; Wang, Y.J; Zhao, Y; Liu, X; Wu, Q Application of quality by design approach to formulate and optimize tripterine loaded in nanostructured lipid carriers for transdermal delivery. J. Drug Deliv. Sci. Technol., 2019, 52, 1032-1041.
[http://dx.doi.org/10.1016/j.jddst.2019.06.006]
[19]
Luruli, N; Pijpers, T; Brüll, R; Grumel, V; Pasch, H; Mathot, V Fractionation of ethylene/1‐pentene copolymers using a combination of SEC‐FTIR and SEC‐HPer DSC. J. Polym. Sci., B, Polym. Phys., 2007, 45(21), 2956-2965.
[http://dx.doi.org/10.1002/polb.21127]
[20]
Injem, V.K; Sudheer, P; Ashwini, M Formulation and evaluation of topical solid lipid nanoparticulate system of clobetasole propionate. Der Pharma Chem., 2017, 9(22), 29-37.
[21]
Bhaskar, K; Krishna Mohan, C; Lingam, M; Prabhakar Reddy, V; Venkateswarlu, V; Madhusudan Rao, Y Development of nitrendipine controlled release formulations based on SLN and NLC for topical delivery: In vitro and ex vivo characterization. Drug Dev. Ind. Pharm., 2008, 34(7), 719-725.
[http://dx.doi.org/10.1080/03639040701842485] [PMID: 18612912]
[22]
Shakeel, F; Baboota, S; Ahuja, A; Ali, J; Shafiq, S Skin permeation mechanism and bioavailability enhancement of celecoxib; Curr Res Pharm Technol, 2011, pp. 107-120.
[23]
Singh Hallan, S; Sguizzato, M; Pavoni, G; Baldisserotto, A; Drechsler, M; Mariani, P; Esposito, E; Cortesi, R Ellagic acid containing nanostructured lipid carriers for topical application: A preliminary study. Molecules, 2020, 25(6), 1449.
[http://dx.doi.org/10.3390/molecules25061449] [PMID: 32210106]
[24]
Vijayan, V; Jayachandran, E; Anburaj, J; Rao, D.S; Kumar, K.J Transdermal delivery of repaglinide from solid lipid nanoparticles in diabetic rats: In vitro and in vivo Studies. J Pharm Sci Res., 2011, 3(3), 1077.
[25]
Nayak, B; Pattanayak, D; Ellaiah, P; Das, S Formulation design preparation and in vitro characterization of nebivolol transdermal patches. Asian J. Pharm., 2011, 5(3), 175-182.
[http://dx.doi.org/10.4103/0973-8398.91994]
[26]
Trivedi, D; Goyal, A Formulation and evaluation of transdermal patches containing dexketoprofen trometamol. Int. J. Pharm. Chem. Anal., 2020, 7(2), 87-97.
[http://dx.doi.org/10.18231/j.ijpca.2020.014]
[27]
Seyed Yagoubi, A; Shahidi, F; Mohebbi, M; Varidi, M; Golmohammadzadeh, S Preparation, characterization and evaluation of physicochemical properties of phycocyanin-loaded solid lipid nanoparticles and nanostructured lipid carriers. J. Food Meas. Charact., 2018, 12(1), 378-385.
[http://dx.doi.org/10.1007/s11694-017-9650-y]
[28]
Bhowmick, M Evaluation and characterization of transdermal therapeutic systems: An exhaustive pictorial and figurative review. J. Drug Deliv. Ther., 2016, 4(6), 8-22.
[29]
Banerjee, S; Chattopadhyay, P; Ghosh, A; Pathak, M.P; Singh, S; Veer, V Acute dermal irritation, sensitization, and acute toxicity studies of a transdermal patch for prophylaxis against (+/-) anatoxin-a poisoning. Int. J. Toxicol., 2013, 32(4), 308-313.
[http://dx.doi.org/10.1177/1091581813489996] [PMID: 23696561]
[30]
Mandava, K; Cherukuri, S; Batchu, U.R; Cherukuri, V; Ganapuram, K Formulation and evaluation of transdermal drug delivery of topiramate. Int. J. Pharm. Investig., 2017, 7(1), 10-17.
[http://dx.doi.org/10.4103/jphi.JPHI_35_16] [PMID: 28405574]
[31]
Nair, A; Jacob, S A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm., 2016, 7(2), 27-31.
[http://dx.doi.org/10.4103/0976-0105.177703] [PMID: 27057123]
[32]
Li, Y; Wei, Y; Zhang, F; Wang, D; Wu, X Changes in the pharmacokinetics of glibenclamide in rats with streptozotocin-induced diabetes mellitus. Acta Pharm. Sin. B, 2012, 2(2), 198-204.
[http://dx.doi.org/10.1016/j.apsb.2012.01.005]
[33]
Tipre, D.N; Vavia, P.R Formulation optimization and stability study of transdermal therapeutic system of nicorandil. Pharm. Dev. Technol., 2002, 7(3), 325-332.
[http://dx.doi.org/10.1081/PDT-120005729] [PMID: 12229264]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy